The Journal of Infectious Diseases · 1997 · 130 citations · 9 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccinologyVirologyHuman Papillomavirus InfectionOncogenic VirusesVaccinationViral InfectionsViral VaccinesVirus-like Particle VaccinesExperimental Animal Models Of Viral InfectionImmune Response To HpvMucosal Human Papillomavirus InfectionPreventive ImmunizationRecombinant Virus-like ParticlesTherapeutic Hpv VaccinesViral Challenge ExperimentsVirus-like Particles
It has been shown previously that immunization of animals with recombinant virus-like particles (VLPs) consisting of the viral capsid proteins L1 or L1 plus L2 protected animals against experimental viral challenge. However, none of these experimental models addresses the issue of whether systemic immunization with VLPs elicits a neutralizing antibody response in the genital mucosa. Such a response may be necessary to protect the uterine cervix against infection with genital human papillomavirus (HPV) types. African green monkeys systemically immunized with HPV-11 VLPs expressed in Saccharomyces cerevisiae and formulated on aluminum adjuvant elicited high-titered HPV-11 VLP-specific serum antibody responses. Sera from these immunized monkeys neutralized HPV-11 in the athymic mouse xenograft system. Significant levels of HPV-11-neutralizing antibodies also were observed in cervicovaginal secretions. These findings suggest that protection against HPV infection of the uterine cervix may be possible through systemic immunization with HPV VLPs.
9
Protection Against Vaginal SIV Transmission with Microencapsulated Vaccine
Preston A. Marx, Richard W. Compans, Agegnehu Gettie et al. · Science · 1993 · 262 citations
Neil D. Christensen, Reinhard Höpfl, Susan DiAngelo et al. · Journal of General Virology · 1994 · 155 citations